CSN Login
Members Online: 4

You are here

Research study for sexual dysfunction in prostate cancer patients.

Date: 
Monday, February 4, 2019 - 6:30pm
Your announcement.: 

PI: Erik Wibowo, PhD (University of Otago)

Collaborator: Charlene Rapsey, PhD, PGDipCIPs (University of Otago)

Background: Sexual dysfunction is common among men after receiving prostate cancer treatment. Many couples stop sexual activity when the patients have sexual dysfunction, but some remain sexually active.

Aim: Our team plans to assess what strategies prostate cancer patients use to maintain sexual activity.

Eligibility: The study is open to all prostate cancer patients following treatment. 

Procedure: The survey takes about 15 minutes to complete and only needs to be completed once. At the end of the survey, participants can enter a raffle for a chance to win a $100 NZD gift card.

Potential Outcomes: Data from this study can potentially be used by health care providers to advice prostate cancer patients on how to remain sexually active.

 

The above research study announcement posted on Cancer Survivors Network is intended to be informational in nature. The American Cancer Society does not warrant or guarantee the accuracy of the information provided and will not oversee or otherwise be involved in the conduct of the actual research study.  We recommend that you consult with your health care provider if you have concerns about your health before participating in any research study.  Any information you obtain through CSN announcements should not be used as a substitute for consultation with your health care provider.

Web site URL (if applicable): 
http://j.mp/2QxSDid
Check the appropriate category for your announcement: 
Research study, clinical trial, focus group,etc (Requires IRB review and certification. See here for guidelines.)
Contact - Email: 
erik.wibowo@otago.ac.nz
Contact - First name: 
Erik
Contact - Last name: 
Wibowo
Contact - Telephone number: 
+6434704692
Subscribe to Comments for "Research study for sexual dysfunction in prostate cancer patients."